How Geographic Atrophy Impacts Functional Outcomes
Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.
Rethinking Psychiatry With Dr. Steve Levine: Episode 3
Dr. Levine is joined by Dr. Sanjay Mathew to talk about some exciting treatments in the pipeline for psychiatric disorders.
Advances in Anti-VEGF Administration: From Port Delivery to Subcutaneous
Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.
Progression in Complement Inhibitors, Retina Gene Therapies
Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.
What Fish Oil Supplements May Provide to Retina Disease Management
An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.
Phase 4 Elevatum Trial Will Observe Faricimab In Underrepresented DME Populations
Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.
Sarcoidosis Screening, Clinical Research Improving with Awareness Efforts
How To Better Track, Interpret Air Quality Data
Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.
The Uterine Fibroid Treatment and Telemedicine Landscape
Erica Marsh, MD, MSCI, discusses the role of new drug classes like GnRH antagonists, as well as the adoption of remote screening options following COVID-19 response.
How Racial Disparities, Personal Stigma Persist in Uterine Fibroid Care
Erica Marsh, MD, MSCI, discusses the need for improved patient involvement and open discussion in the highly prevalent, potentially psychologically impactful condition.
State of the Science: Managing C Difficile Infections
There are several emerging treatments for C difficile infections.
What's Driving Turnover in Health Care During COVID-19?
Bianca K. Frogner, PhD, discusses the prevalence of burnout and job dissatisfaction observed across various health care worker roles and settings.
Miriam Vos, MD: Future Research For Pediatric NAFLD
ALT can be used a marker for NAFLD severity in pediatric patients.
Addressing Challenges in Depression Treatment
There is a need for new medications for depression to overcome high rates of treatment resistance.
Miriam Vos, MD: Studying Pediatric Patients With NAFLD
The prevalence of NAFLD in the pediatric population has increased in recent years.
Institutional Perspectives in Rheumatology: ANCA-associated Vasculitis
Dr. Kenneth J. Warrington led the panel in discussing various topics in rheumatology.
A Preview of the Ziltevekimab ZEUS Clinical Trial
Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.
Empagliflozin During Hospitalization Improves Acute Heart Failure Symptoms by 15 Days
Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.
CANTOS Data Show Importance of Inflammation Risk in CKD Patients with Atherosclerosis
Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.
Sotagliflozin Reduces MACE Risk in Diabetic, Kidney Disease Patients in SCORED Trial
Study author Deepak L. Bhatt, MD, MPH, discusses the unique SGLT-1 and SGLT-2 inhibition derived from sotagliflozin, and how impactful its benefit may be.
What's Next for Lipoprotein(a) Lowering Agent SLN360
Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.
Evidence Builds for Bentracimab Reversing Antiplatelet Effect of Ticagrelor
Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.
Rivaroxaban Benefits LER Patients Safely Regardless of Chronic Kidney Disease
VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.
Vupanorsen Falls Short Despite HDL-C Reduction in TRANSLATE-TIMI 70
Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.
The Immediate Impact of the 2022 Heart Failure Guidelines
Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.
Milind Desai, MD: Next Steps for Mavacamten for Hypertrophic Cardiomyopathy
Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.
How New Heart Failure Guidelines Recommend SGLT-2 Inhibitor Use
Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.
Will a Drug Get Approved for Epidermylosis Bullosa?
A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.
Advancing Pediatric Dermatology Biologics and Symptom Scoring
Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.
Oleogel-S10 Significantly Improves Epidermolysis Bullosa Wounds at 12 Months
Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.
2 Clarke Drive Cranbury, NJ 08512